Asset Details
Do you wish to reserve the book?
Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker
Do you wish to request the book?
Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker
2021
Overview
A wide range of diseases have been shown to be influenced by the accumulation of senescent cells, from fibrosis to diabetes, cancer, Alzheimer’s and other age-related pathologies. Consistent with this, clearance of senescent cells can prolong healthspan and lifespan in in vivo models. This provided a rationale for developing a new class of drugs, called senolytics, designed to selectively eliminate senescent cells in human tissues. The senolytics tested so far lack specificity and have significant off-target effects, suggesting that a targeted approach could be more clinically relevant. Here, we propose to use an extracellular epitope of B2M, a recently identified membrane marker of senescence, as a target for the specific delivery of toxic drugs into senescent cells. We show that an antibody–drug conjugate (ADC) against B2M clears senescent cells by releasing duocarmycin into them, while an isotype control ADC was not toxic for these cells. This effect was dependent on p53 expression and therefore more evident in stress-induced senescence. Non-senescent cells were not affected by either antibody, confirming the specificity of the treatment. Our results provide a proof-of-principle assessment of a novel approach for the specific elimination of senescent cells using a second generation targeted senolytic against proteins of their surfaceome, which could have clinical applications in pathological ageing and associated diseases.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ Aging
/ beta 2-Microglobulin - metabolism
/ Cellular Senescence - drug effects
/ Duocarmycins - pharmacokinetics
/ Epitopes
/ Fibrosis
/ Gene Expression Regulation - drug effects
/ Humanities and Social Sciences
/ Humans
/ Immunoconjugates - pharmacokinetics
/ Immunoconjugates - pharmacology
/ Science
/ Senotherapeutics - pharmacokinetics
